A5058243253- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Fibroblast Growth Factor Research
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Medical Imaging Techniques and Applications
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Eosinophilic Disorders and Syndromes
- PI3K/AKT/mTOR signaling in cancer
- CNS Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Viral-associated cancers and disorders
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Genetic factors in colorectal cancer
- Melanoma and MAPK Pathways
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
University of Cologne
2011-2025
University Hospital Cologne
2016-2025
Heinrich Heine University Düsseldorf
2020-2024
Düsseldorf University Hospital
2020-2024
Centrum für Integrierte Onkologie
2010-2022
Integrated Oncology (United States)
2008-2019
Dana-Farber Cancer Institute
2017
University of Bonn
2013-2015
Max Planck Institute for Metabolism Research
2011-2013
TU Dortmund University
2013
The pattern of mutations in human lung cancer differs by tumor subtype and is a useful addition to histology for selecting targeted therapy improving patient survival.
Purpose This two-part, first-in-human study was initiated in patients with advanced solid tumors harboring genetic alterations fibroblast growth factor receptors (FGFRs) to determine the maximum tolerated dose (MTD), recommended phase II (RP2D), and schedule, safety, pharmacokinetics, pharmacodynamics, antitumor activity of oral BGJ398, a selective FGFR1-3 tyrosine kinase inhibitor. Patients Methods Adult were treated escalating dosages BGJ398 5 150 mg once daily or 50 twice continuously...
IntroductionAlthough KRAS mutations in NSCLC have been considered mutually exclusive driver for a long time, there is now growing evidence that KRAS-mutated represents genetically heterogeneous subgroup. We sought to determine genetic heterogeneity with respect cancer-related co-mutations and their correlation different mutation subtypes.MethodsDiagnostic samples from 4507 patients were analyzed by next-generation sequencing using panel of 14 genes and, subset patients, fluorescence situ...
BackgroundWe analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC).Patients and methodsALK-rearranged stage IIIB/IV NSCLC patients were with next-generation sequencing fluorescence situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) overall (OS) determined total cohort treatment-related sub-cohorts. Cox regression carried out to exclude...
Positron emission tomography (PET) with both 2'-deoxy-2'-[(18)F]fluoro-D-glucose (FDG) and 3'-[(18)F]fluoro-3'-deoxy-L-thymidine (FLT) was evaluated respect to the accuracy of early prediction nonprogression following erlotinib therapy, independent from epidermal growth factor receptor (EGFR) mutational status, in patients previously untreated advanced non-small-cell lung cancer (NSCLC).Thirty-four stage IV NSCLC were this phase II trial. Changes FDG FLT uptake after 1 (early) 6 (late) weeks...
Somatic mutations of the PIK3CA gene have been described in non-small cell lung cancer (NSCLC), but limited data is available on their biological relevance. This study was performed to characterize PIK3CA-mutated NSCLC clinically and genetically.Tumor tissue collected consecutively from 1144 patients within a molecular screening network between March 2010 2012 analyzed for using dideoxy-sequencing next-generation sequencing (NGS). Clinical, pathological, genetic characteristics are compared...
To evaluate treatment outcome and prognostic factors in patients with refractory or first relapsed Hodgkin's disease (HD) treated salvage radiotherapy (SRT) alone.From 4,754 registered the database of German Hodgkin Study Group from 1988 to 1999, 624 were identified progressive (n = 202), early 170) late 252) HD. At failure, SRT alone was given 100 patients. Patient characteristics were: median age, 36 years; disease, 47%; relapse, 23%; 30%; "B" symptoms, 14%. Eighty-five percent after...
The 8p12 locus (containing the FGFR1 tyrosine kinase gene) is frequently amplified in squamous cell lung cancer. However, it currently unknown which of 8p12-amplified tumors are also sensitive to fibroblast growth factor receptor (FGFR) inhibition. We found that, contrast with other recurrent amplifications, region included multiple centers amplification, suggesting marked genomic heterogeneity. FGFR1-amplified tumor cells were dependent on FGFR ligands vitro and vivo. Furthermore, ectopic...
The purpose of this study was to evaluate the relevance for prediction clinical benefit first-line treatment with erlotinib using different quantitative parameters PET both <sup>18</sup>F-FDG and 3′-deoxy-3′-<sup>18</sup>F-fluorothymidine (<sup>18</sup>F-FLT) in patients advanced non–small cell lung cancer. <b>Methods:</b> Data were used from a prospective trial involving untreated stage IV <sup>18</sup>F-FLT performed before 1 (early) 6 (late) weeks after treatment. Several standardized...
To determine whether epoetin alfa reduces anemia-related fatigue, improves other aspects of health-related patient-recorded outcomes (PROs), the number RBC transfusions, and has an impact on freedom from treatment failure (FFTF) overall survival (OS) in patients with advanced-stage Hodgkin's lymphoma (HL).The prospectively randomized HD15EPO study performed by German Hodgkin Study Group investigated administered at doses 40,000 U weekly during after chemotherapy (six to eight cycles...
Abstract The family of fibroblast growth factors (FGFs) and FGF receptors (FGFRs) plays a critical role in cell proliferation survival. A variety genetic alterations (e.g. amplifications, mutations, translocations) these ligands have been found diverse types tumors. NVP-BGJ398 is potent, selective, orally bioavailable inhibitor the FGFR tyrosine kinases. It inhibits various FGFR-dependent lines at nano-molar concentrations including breast lung cancers harboring FGFR1 amplification,...
The aim was to assess the value of tumor lesion glycolysis (TLG) and proliferation (TLP) determined by FDG 3'-deoxy-3'-F-fluorothymidine (FLT) PET for response prediction prognostic differentiation in patients with advanced non-small cell lung cancer (NSCLC) treated erlotinib.FDG-PET FLT-PET were performed 30 untreated Stage IV NSCLC before start therapy, 1 (early) 6 (late) weeks after erlotinib treatment. Functional volume parameters including TLG FDG-PET TLP measured sum up 5 lesions per...